Champions Oncology, Inc. (CSBR)
5.45
+0.30
(+5.83%)
USD |
NASDAQ |
Sep 03, 13:40
Champions Oncology Research and Development Expense (TTM) : 9.084M for April 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| April 30, 2026 | 9.084M |
| January 31, 2026 | 8.932M |
| October 31, 2025 | 8.38M |
| July 31, 2025 | 7.453M |
| April 30, 2025 | 6.825M |
| January 31, 2025 | 6.911M |
| October 31, 2024 | 7.378M |
| July 31, 2024 | 8.204M |
| April 30, 2024 | 9.543M |
| January 31, 2024 | 10.35M |
| October 31, 2023 | 11.36M |
| July 31, 2023 | 11.45M |
| April 30, 2023 | 11.54M |
| January 31, 2023 | 11.28M |
| October 31, 2022 | 10.26M |
| July 31, 2022 | 9.957M |
| April 30, 2022 | 9.374M |
| January 31, 2022 | 8.854M |
| October 31, 2021 | 8.552M |
| July 31, 2021 | 7.903M |
| April 30, 2021 | 7.196M |
| January 31, 2021 | 6.945M |
| October 31, 2020 | 6.457M |
| July 31, 2020 | 6.148M |
| April 30, 2020 | 5.854M |
| Date | Value |
|---|---|
| January 31, 2020 | 5.283M |
| October 31, 2019 | 5.161M |
| July 31, 2019 | 5.013M |
| April 30, 2019 | 4.798M |
| January 31, 2019 | 4.644M |
| October 31, 2018 | 4.42M |
| July 31, 2018 | 4.342M |
| April 30, 2018 | 4.372M |
| January 31, 2018 | 4.354M |
| October 31, 2017 | 4.307M |
| July 31, 2017 | 4.20M |
| April 30, 2017 | 4.293M |
| January 31, 2017 | 4.393M |
| October 31, 2016 | 4.394M |
| July 31, 2016 | 4.305M |
| April 30, 2016 | 4.194M |
| January 31, 2016 | 4.106M |
| October 31, 2015 | 4.20M |
| July 31, 2015 | 4.53M |
| April 30, 2015 | 4.853M |
| January 31, 2015 | 4.416M |
| October 31, 2014 | 3.858M |
| July 31, 2014 | 3.286M |
| April 30, 2014 | 2.265M |
| January 31, 2014 | 2.119M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Medpace Holdings, Inc. | -- |
| Avantor, Inc. | -- |
| Personalis, Inc. | 56.12M |
| Adaptive Biotechnologies Corp. | 80.01M |
| 10X Genomics, Inc. | 226.80M |